UnitedHealth Group Incorporated $UNH Stake Lessened by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its position in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 7.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,641 shares of the healthcare conglomerate’s stock after selling 20,559 shares during the period. Janney Montgomery Scott LLC’s holdings in UnitedHealth Group were worth $101,265,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its position in shares of UnitedHealth Group by 176.2% during the 4th quarter. Brighton Jones LLC now owns 44,249 shares of the healthcare conglomerate’s stock valued at $22,384,000 after purchasing an additional 28,231 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in UnitedHealth Group by 137.1% during the fourth quarter. Revolve Wealth Partners LLC now owns 4,019 shares of the healthcare conglomerate’s stock worth $2,033,000 after buying an additional 2,324 shares in the last quarter. CMT Capital Markets Trading GmbH bought a new position in shares of UnitedHealth Group in the second quarter valued at $340,000. Flow Traders U.S. LLC bought a new stake in shares of UnitedHealth Group during the 2nd quarter worth $356,000. Finally, Jump Financial LLC acquired a new stake in shares of UnitedHealth Group during the second quarter worth $377,000. Institutional investors own 87.86% of the company’s stock.

Wall Street Analysts Forecast Growth

UNH has been the subject of a number of recent analyst reports. HSBC increased their price target on UnitedHealth Group from $300.00 to $380.00 and gave the company a “hold” rating in a research report on Monday, July 6th. Royal Bank Of Canada lifted their target price on shares of UnitedHealth Group from $463.00 to $478.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of UnitedHealth Group in a research note on Tuesday, July 21st. BMO Capital Markets set a $512.00 target price on shares of UnitedHealth Group in a research note on Tuesday, July 21st. Finally, HC Wainwright set a $492.00 price objective on UnitedHealth Group in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $455.92.

UnitedHealth Group News Roundup

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: UnitedHealth authorized a dividend, reinforcing shareholder returns and signaling confidence in its financial position. However, the announcement comes amid an ongoing governance lawsuit, which may limit its positive impact. UnitedHealth Group Authorizes Dividend Amid Governance Lawsuit
• Positive Sentiment: Wall Street’s average brokerage recommendation remains favorable, suggesting analysts believe UnitedHealth’s valuation and earnings outlook could support the shares. The bullish view is tempered by the tendency of sell-side recommendations to skew optimistic. Wall Street Bulls Look Optimistic About UnitedHealth
• Neutral Sentiment: The expected guilty plea by Luigi Mangione in the federal case involving the killing of UnitedHealthcare CEO Brian Thompson could bring additional clarity to a high-profile event, but it does not materially change UnitedHealth’s operating outlook. Luigi Mangione Reportedly Set to Plead Guilty
• Negative Sentiment: A shareholder lawsuit alleges UnitedHealth misled investors, failed to address governance and cybersecurity weaknesses, and discontinued an internal Medicare billing audit before the Change Healthcare cyberattack. The claims increase potential legal, regulatory and reputational risks. Investor Suit Says UnitedHealth Ignored Governance and Cybersecurity Gaps
• Negative Sentiment: A derivative lawsuit reportedly says executives knew that patients won roughly 90% of appeals against AI-generated claim denials. The allegation raises concerns about the accuracy of automated utilization management, potential compliance costs and damage to UnitedHealth’s reputation. UNH Patients Win 90% of AI Denial Appeals
• Negative Sentiment: An investor analysis argues that margin recovery is already reflected in UnitedHealth’s valuation, leaving future earnings growth as the next major test. This limits upside if revenue or membership growth disappoints. UnitedHealth Margin Recovery Is Priced In

Insider Activity at UnitedHealth Group

In other news, CEO Patrick Hugh Conway sold 500 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $410.00, for a total transaction of $205,000.00. Following the transaction, the chief executive officer owned 16,497 shares in the company, valued at approximately $6,763,770. This trade represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.19% of the stock is currently owned by company insiders.

UnitedHealth Group Trading Down 1.7%

UnitedHealth Group stock opened at $395.02 on Tuesday. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 0.66. UnitedHealth Group Incorporated has a 12 month low of $255.96 and a 12 month high of $461.62. The company’s fifty day simple moving average is $415.52 and its 200-day simple moving average is $353.65. The stock has a market cap of $354.57 billion, a P/E ratio of 25.42, a P/E/G ratio of 1.40 and a beta of 0.62.

UnitedHealth Group (NYSE:UNH) last issued its earnings results on Thursday, July 16th. The healthcare conglomerate reported $6.38 EPS for the quarter, beating analysts’ consensus estimates of $4.94 by $1.44. UnitedHealth Group had a return on equity of 16.53% and a net margin of 3.14%.The firm had revenue of $112.03 billion for the quarter, compared to the consensus estimate of $110.81 billion. During the same quarter in the previous year, the company posted $4.08 earnings per share. The business’s quarterly revenue was up .4% compared to the same quarter last year. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. As a group, sell-side analysts forecast that UnitedHealth Group Incorporated will post 19.69 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 22nd. Investors of record on Monday, September 14th will be given a dividend of $2.32 per share. This represents a $9.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Monday, September 14th. UnitedHealth Group’s dividend payout ratio (DPR) is presently 59.72%.

UnitedHealth Group Profile

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.